Triple

T16185342
Position Surface form Disambiguated ID Type / Status
Subject Office of Pharmaceutical Quality E392785 entity
Predicate worksWith P398 FINISHED
Object Office of Generic Drugs
The Office of Generic Drugs is a division of the U.S. Food and Drug Administration responsible for reviewing and approving generic medications to ensure they are safe, effective, and therapeutically equivalent to brand-name drugs.
E1199970 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Office of Generic Drugs | Statement: [Office of Pharmaceutical Quality, worksWith, Office of Generic Drugs]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Office of Generic Drugs
Context triple: [Office of Pharmaceutical Quality, worksWith, Office of Generic Drugs]
  • A. Center for Drug Evaluation and Research chosen
    The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
  • B. Office of Pharmaceutical Quality
    The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
  • C. Office of Orphan Products Development
    The Office of Orphan Products Development is a U.S. Food and Drug Administration office that promotes the development of drugs and other medical products for rare diseases and conditions.
  • D. Office of Pharmacy Affairs
    The Office of Pharmacy Affairs is a division within the U.S. Health Resources and Services Administration that oversees federal drug discount initiatives for safety-net healthcare providers.
  • E. Office of Regulatory Affairs
    The Office of Regulatory Affairs is the U.S. FDA’s primary field organization responsible for inspecting regulated products and manufacturers, enforcing compliance, and overseeing import operations to protect public health.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Office of Generic Drugs
Triple: [Office of Pharmaceutical Quality, worksWith, Office of Generic Drugs]
Generated description
The Office of Generic Drugs is a division of the U.S. Food and Drug Administration responsible for reviewing and approving generic medications to ensure they are safe, effective, and therapeutically equivalent to brand-name drugs.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Office of Generic Drugs
Target entity description: The Office of Generic Drugs is a division of the U.S. Food and Drug Administration responsible for reviewing and approving generic medications to ensure they are safe, effective, and therapeutically equivalent to brand-name drugs.
  • A. Center for Drug Evaluation and Research
    The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
  • B. Office of Pharmaceutical Quality
    The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
  • C. Office of Orphan Products Development
    The Office of Orphan Products Development is a U.S. Food and Drug Administration office that promotes the development of drugs and other medical products for rare diseases and conditions.
  • D. Office of Pharmacy Affairs
    The Office of Pharmacy Affairs is a division within the U.S. Health Resources and Services Administration that oversees federal drug discount initiatives for safety-net healthcare providers.
  • E. Office of Regulatory Affairs
    The Office of Regulatory Affairs is the U.S. FDA’s primary field organization responsible for inspecting regulated products and manufacturers, enforcing compliance, and overseeing import operations to protect public health.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d87f1e49ac8190a311b54d32990576 completed April 10, 2026, 4:39 a.m.
NER Named-entity recognition batch_69e22060dcf88190b7c662946a5f0191 completed April 17, 2026, 11:58 a.m.
NED1 Entity disambiguation (via context triple) batch_69ffff0550b48190ac84946b7254552b completed May 10, 2026, 3:44 a.m.
NEDg Description generation batch_6a0000a8a74c8190925c4140cf4a8520 completed May 10, 2026, 3:51 a.m.
NED2 Entity disambiguation (via description) batch_6a0004ceda8c8190a358f58f76116a7f completed May 10, 2026, 4:08 a.m.
Created at: April 10, 2026, 5:02 a.m.